Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
Objective: This study aims to investigate the safety and efficacy of abrocitinib in treating moderate-to-severe AD in adolescents and adults.Methods: Pubmed, Cochrane, Embase, and Web of science data base were searched from inception to 9 August 2022. All randomized controlled trials (RCTs) evaluati...
Saved in:
Main Authors: | Ling Li (Author), Jiajun Yu (Author), Baoqing Chen (Author), Ying Guo (Author), Yufeng Yang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis
by: Xu ZHU, et al.
Published: (2023) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023) -
Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis
by: Delphine Staumont‐Sallé, et al.
Published: (2023) -
Preliminary experience with abrocitinib in severe atopic dermatitis
by: Silvia Ferrucci, et al.
Published: (2024) -
Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Hammad Ali Fadlalmola, et al.
Published: (2021)